BioLargo, Inc. (BLGO)
OTCMKTS · Delayed Price · Currency is USD
0.0969
+0.0094 (10.74%)
At close: Sep 8, 2026
BioLargo Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4.08 | 7.77 | 17.78 | 12.23 | 5.88 | 2.53 | |
Revenue Growth | -70.95% | -56.33% | 45.37% | 107.85% | 132.48% | 4.07% |
Cost of Revenue | 2.45 | 4.36 | 9.93 | 6.08 | 3.03 | 1.43 |
Gross Profit | 1.63 | 3.41 | 7.85 | 6.15 | 2.86 | 1.1 |
Selling, General & Admin | 12.59 | 11.77 | 9.3 | 8.06 | 6.73 | 6.17 |
Research & Development | 3.26 | 2.59 | 2.88 | 2.28 | 1.32 | 1.37 |
Other Operating Expenses | - | - | - | 0.01 | -0.06 | -0.02 |
Operating Expenses | 19.74 | 18.25 | 12.18 | 10.35 | 7.99 | 7.52 |
Operating Income | -18.11 | -14.84 | -4.33 | -4.2 | -5.13 | -6.42 |
Interest Expense | -0.81 | -0.54 | -0.07 | -0.09 | -0.05 | -0.23 |
Interest & Investment Income | 0.22 | 0.2 | 0.04 | - | - | - |
Other Non Operating Income (Expenses) | -0.09 | 0.01 | -0.08 | 0.04 | 0.07 | 0.06 |
EBT Excluding Unusual Items | -18.78 | -15.18 | -4.44 | -4.25 | -5.11 | -6.6 |
Asset Writedown | -0.01 | -0.01 | - | -0.39 | -0.2 | -0.34 |
Other Unusual Items | - | - | 0.1 | - | 0.17 | 0.04 |
Pretax Income | -18.79 | -15.19 | -4.35 | -4.65 | -5.13 | -6.89 |
Earnings From Continuing Operations | -18.79 | -15.19 | -4.35 | -4.65 | -5.13 | -6.89 |
Minority Interest in Earnings | 4.31 | 3.41 | 1.95 | 1.14 | 0.66 | -0.19 |
Net Income | -14.49 | -11.78 | -2.4 | -3.5 | -4.47 | -7.08 |
Net Income to Common | -14.49 | -11.78 | -2.4 | -3.5 | -4.47 | -7.08 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 316 | 307 | 298 | 286 | 268 | 247 |
Shares Outstanding (Diluted) | 316 | 307 | 298 | 286 | 268 | 247 |
Shares Change | 4.71% | 2.96% | 4.25% | 6.58% | 8.54% | 26.13% |
EPS (Basic) | -0.05 | -0.04 | -0.01 | -0.01 | -0.02 | -0.03 |
EPS (Diluted) | -0.05 | -0.04 | -0.01 | -0.01 | -0.02 | -0.03 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -10.56 | -8.34 | -4.44 | -2.84 | -3.03 | -3.96 |
Free Cash Flow Per Share | -0.03 | -0.03 | -0.01 | -0.01 | -0.01 | -0.02 |
Gross Margin | 39.91% | 43.86% | 44.17% | 50.32% | 48.55% | 43.58% |
Operating Margin | -443.61% | -191.13% | -24.36% | -34.33% | -87.19% | -253.50% |
Profit Margin | -354.88% | -151.71% | -13.51% | -28.65% | -76.02% | -279.73% |
Free Cash Flow Margin | -258.70% | -107.44% | -24.98% | -23.25% | -51.55% | -156.38% |
EBITDA | -17.95 | -14.7 | -4.18 | -4.1 | -5.09 | -6.4 |
EBITDA Margin | - | -189.26% | -23.49% | -33.49% | -86.42% | -252.71% |
D&A For EBITDA | 0.16 | 0.15 | 0.16 | 0.1 | 0.05 | 0.02 |
EBIT | -18.11 | -14.84 | -4.33 | -4.2 | -5.13 | -6.42 |
EBIT Margin | - | -191.13% | -24.36% | -34.33% | -87.19% | -253.50% |
Revenue as Reported | 4.08 | 7.77 | 17.78 | 12.23 | 5.88 | 2.53 |